Elizabeth H. Cull

Dr. Elizabeth H. Cull

Oncology | Hematology Oncology
65 International Drive, 
Greenville, SC 
On Staff At
Accepting New Patients
65 International Drive, 
Greenville, SC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Elizabeth Cull is a Hematologist Oncology specialist and an Oncologist in Greenville, South Carolina. Dr. Cull is rated as an Experienced provider by MediFind in the treatment of Factor 7 Deficiency. Her top areas of expertise are Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, Multiple Myeloma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Cull is currently accepting new patients.

Her clinical research consists of co-authoring 16 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Bowman Gray School Of Medicine Of Wake Forest University
Residency
Northwestern University Medical School
Specialties
Oncology
Hematology Oncology
Licenses
Internal Medicine in IL
Board Certifications
American Board Of Internal Medicine
Fellowships
Northwestern University Medical School
Hospital Affiliations
Prisma Health Greer Memorial Hospital
Prisma Health Greenville Memorial Hospital
Prisma Health Patewood Hospital
Prisma Health Baptist Easley Hospital
Prisma Health Hillcrest Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Prisma Health Cancer Institute – Eastside
65 International Drive, Greenville, SC 29615

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Multicenter, Phase 1/2 Study of Selinexor in Combination With Backbone Treatments or Novel Therapies in Patients With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
A Multicenter, Phase 1/2 Study of Selinexor in Combination With Backbone Treatments or Novel Therapies in Patients With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
Enrollment Status: Withdrawn
Publish Date: October 03, 2025
Intervention Type: Drug
Study Drugs: Selinexor, Rituximab, Bendamustine, Polatuzumab Vedotin, Ibrutinib, Lenalidomide, Tafasitamab, Venetoclax, Gemcitabine, Oxaliplatin
Study Phase: Phase 1/Phase 2
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients With Relapsed or Refractory Lymphoma
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients With Relapsed or Refractory Lymphoma
Enrollment Status: Terminated
Publish Date: September 17, 2025
Intervention Type: Drug
Study Drug: HMPL-523
Study Phase: Phase 1
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2025
Intervention Type: Drug, Other
Study Drugs: Brentuximab vedotin, Rituximab, Lenalidomide
Study Phase: Phase 3
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Enrollment Status: Completed
Publish Date: March 30, 2025
Intervention Type: Drug
Study Drugs: Zanubrutinib, Ibrutinib
Study Phase: Phase 3
A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed / Refractory Multiple Myeloma - DREAMM-6
A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed / Refractory Multiple Myeloma - DREAMM-6
Enrollment Status: Completed
Publish Date: March 18, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Lenalidomide, Dexamethasone, Bortezomib
Study Phase: Phase 1/Phase 2
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
Enrollment Status: Terminated
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drug: CG-806
Study Phase: Phase 1
A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-2)
A Phase 2 Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-2)
Enrollment Status: Completed
Publish Date: August 29, 2023
Intervention Type: Drug
Study Drug: Loncastuximab tesirine
Study Phase: Phase 2
A Phase Ia/b Dose Escalation and Expansion, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of APTO-253 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplasia
A Phase Ia/b Dose Escalation and Expansion, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of APTO-253 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia or High-Risk Myelodysplasia
Enrollment Status: Terminated
Publish Date: August 22, 2022
Intervention Type: Drug
Study Drug: APTO-253
Study Phase: Phase 1
Phase 1b, Open Label Study to Evaluate Safety and Efficacy of TRU-016 in Combination With Rituximab, Obinutuzumab, Rituximab and Idelalisib, or Ibrutinib in Chronic Lymphocytic Leukemia and With Bendamustine in Peripheral T-cell Lymphoma
Phase 1b, Open Label Study to Evaluate Safety and Efficacy of TRU-016 in Combination With Rituximab, Obinutuzumab, Rituximab and Idelalisib, or Ibrutinib in Chronic Lymphocytic Leukemia and With Bendamustine in Peripheral T-cell Lymphoma
Enrollment Status: Terminated
Publish Date: May 20, 2021
Intervention Type: Biological
Study Drugs: Rituximab, Obinutuzumab, Idelalisib, Ibrutinib, Bendamustine, TRU-016
Study Phase: Phase 1
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No_longer_available
Publish Date: July 15, 2020
Intervention Type: Drug
View 9 Less Clinical Trials

16 Total Publications

Feasibility and Clinical Utility of Patient-Reported Outcome Measurement Information System-29 in a Newly Established Adolescent and Young Adult Oncology Program.
Feasibility and Clinical Utility of Patient-Reported Outcome Measurement Information System-29 in a Newly Established Adolescent and Young Adult Oncology Program.
Journal: Journal of adolescent and young adult oncology
Published: July 03, 2024
Similar Doctors
Experienced in Factor 7 Deficiency
Dr. Jay B. Nayak
Hematology Oncology | Hematology | Oncology
Experienced in Factor 7 Deficiency
Dr. Jay B. Nayak
Hematology Oncology | Hematology | Oncology

Anderson Oncology-Hematology Clinic PA

2000 E Greenville St, Suite 5000, 
Anderson, SC 
 (27.4 miles away)
864-512-1658
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jay Nayak is a Hematologist Oncology specialist and a Hematologist in Anderson, South Carolina. Dr. Nayak is rated as a Distinguished provider by MediFind in the treatment of Factor 7 Deficiency. His top areas of expertise are Colorectal Cancer, Lung Cancer, Familial Colorectal Cancer, Small Cell Lung Cancer (SCLC), and Bone Marrow Aspiration. Dr. Nayak is currently accepting new patients.

John K. Hill
Experienced in Factor 7 Deficiency
Dr. John K. Hill
Hematology Oncology | Hematology | Oncology
Experienced in Factor 7 Deficiency
Dr. John K. Hill
Hematology Oncology | Hematology | Oncology

Henderson County Hospital Corporation

805 6th Ave W, 
Hendersonville, NC 
 (33.5 miles away)
828-696-1330
Languages Spoken:
English
See accepted insurances
Accepting New Patients

John Hill is a Hematologist Oncology specialist and a Hematologist in Hendersonville, North Carolina. Dr. Hill is rated as a Distinguished provider by MediFind in the treatment of Factor 7 Deficiency. His top areas of expertise are Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), Monoclonal Gammopathy of Undetermined Significance (MGUS), and Large-Cell Immunoblastic Lymphoma. Dr. Hill is currently accepting new patients.

Jay D. Walls
Experienced in Factor 7 Deficiency
Dr. Jay D. Walls
Oncology | Hematology Oncology
Experienced in Factor 7 Deficiency
Dr. Jay D. Walls
Oncology | Hematology Oncology

Prisma Health Cancer Institute – Grove Commons

3 Butternut Drive, Suite B, 
Greenville, SC 
 (6.2 miles away)
864-241-7272
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Jay Walls is a Hematologist Oncology specialist and an Oncologist in Greenville, South Carolina. Dr. Walls is rated as a Distinguished provider by MediFind in the treatment of Factor 7 Deficiency. His top areas of expertise are Essential Thrombocythemia, Childhood Iron Deficiency Anemia, Sickle Cell Disease, Hemoglobin SC Disease, and Bone Marrow Aspiration. Dr. Walls is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cull's expertise for a condition
ConditionClose
    View All 9 Distinguished Conditions
    View All 26 Advanced Conditions
    View All 73 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile